25-Apr-2006
2nd Annual Specialty Pharmaceuticals Global Summit
Summary
Specialty Pharma transformations and venture investments have continued to grow at an unprecedented pace. The 2006 meeting is an elite opportunity for Big Pharma, Biotech, and Drug Delivery to network with the industry's fastest growing Specialty Pharma companies and discover what makes them so attractive as a partner.
Last Updated: 27-Aug-2010
Specialty Pharma transformations and venture investments have continued to grow at an unprecedented pace. The 2006 meeting is an elite opportunity for Big Pharma, Biotech, and Drug Delivery to network with the industry's fastest growing Specialty Pharma companies and discover what makes them so attractive as a partner.
State of the Industry Panel Discussions:
- Specialty Pharma Awareness to Attract Big Pharma Portfolio Divestitures
- Therapeutic Area Specialization: What Does the Future Hold and What are the Unmet Areas for Lucrative Opportunities?
- Partnering in Specialty Pharma: A Novel & Profitable Business Model for the Pharmaceutical Industry
- What Venture Capitalists Want in a Specialty Pharma Investment & How Long Will They Continue to Invest in Specialty Pharma?
DISTINGUISHED BOARD OF ADVISORS
| Dan Marino, MSc Executive Editorial Director DRUG DELIVERY TECHNOLOGY & SPECIALTY PHARMA MAGAZINES | Cindy H. Dubin Editor-in-Chief SPECIALTY PHARMA MAGAZINE | Woody Bryan, Ph.D. Vice President, Business Development SUPERNUS PHARMACEUTICALS, INC. |
| Vik Seoni, MBA Senior Director, Business Development ENDO PHARMACEUTICALS |
Howard S. Wachtler CEO ACTINIUM PHARMACEUTICALS | Kathleen Williams, Ph.D., JD Co-Chair Life Sciences Practice EDWARDS ANGELL PALMER & DODGE LLP |
| Christine C. Mayer VP, Global Business Development & Licensing BIOVAIL PHARMACEUTICALS, INC. | Mark Horn Director, Finance and R&D Portfolio Management WYETH |
PARTICIPANTS INCLUDE:
|
|
